The National Times - Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine

Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine


Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine
Pfizer Q1 revenues jump 77% to $25.7 bn on Covid-19 vaccine / Photo: © AFP/File

Pfizer reported another quarter of huge revenues growth because of its Covid-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.

Change text size:

The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the Covid vaccine taking in $13.2 billion.

Net income jumped 61 percent to $7.9 billion.

Pfizer confirmed its full-year revenues forecast, in which about just over half of total sales stem from the Covid-19 innoculation and from Paxlovid, the company's therapeutic to treat the coronavirus.

Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.

The company is also exploring "potential next-generation vaccines, including variant vaccines" for the fall season, Chief Executive Albert Bourla said in prepared remarks.

In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.

The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.

But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.

Pfizer now sees full-year adjusted profits of $6.25 to $6.45 a share, down 10 cents from the previous range.

The company attributed the lowered forecast to an accounting change in research and development expenses and to changes in the foreign exchange market that have seen the dollar rise compared with other major currencies.

Shares of Pfizer dipped 1.2 percent to $47.77 in pre-market trading.

T.Cunningham--TNT

Featured

Langley Businesses Navigate Tariff Pressures Amid Holiday Shopping Push

Independent businesses in Langley are facing heightened financial pressures from recent tariff implementations as they navigate the crucial holiday shopping period. While supply chain disruptions threaten inventory and pricing, local advocates highlight that spending at community retailers recirculates significantly more wealth within the region than purchases made through multinational or online platforms.

ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances

In an interview with BERLINER TAGESZEITUNG, the shareholders of Alix Lasers GmbH in Austria said that, after acquiring 100 per cent of the company’s shares, they removed Michael Sobitsch from his position as managing director yesterday, 19 November 2026, in Vienna, Austria. In view of the circumstances, they removed him from office with immediate effect, without granting him discharge for his tenure as managing director.

Analysts Identify Key Metal Stocks Amid 38% Commodity Slide

With silver, copper, and gold prices falling up to 38% from recent peaks due to global economic concerns, technical analysts at Angel One and SAMCO Securities have identified specific trading opportunities in major metal equities. The firms' research highlights both bearish setups for stocks like Hind Copper and SAIL, alongside potential bullish breakouts for APL Apollo Tubes and Jindal Stainless.

Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year

Saudi Arabia's Public Investment Fund (PIF) has been named the world’s most valuable sovereign wealth fund brand for the third consecutive year, according to a new assessment by Brand Finance. The ranking highlights the fund's growing global influence and financial strength as it advances its strategic objectives under Vision 2030.

Change text size: